Testicular Cancer | Dr. Tony Talebi discusses the Treatment of Seminomatous Testicular Cancer

2 Views

07/16/23

Dr Tony Talebi discusses the Treatment of Seminomatous Testicular Cancer with Dr Benedetto. For further discussion visit http://www.HemOnc101.com

Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084

Treatment of seminoma testicular cancer
Testicular cancer is the most common solid malignancy affecting males between the ages of 15 and 35, although it accounts for about 1 percent of all cancers in men. Germ cell tumors (GCTs) account for 95 percent of testicular cancers. They may consist of one predominant histologic pattern, or represent a mix of multiple histologic types.

For treatment purposes, two broad categories of testis tumors are recognized: pure seminoma (no nonseminomatous elements present), and all others, which together are termed nonseminomatous germ cell tumors (NSGCTs). In most series, the ratio of seminoma to NSGCT is about one.

Testicular cancer has become one of the most curable of solid neoplasms because of remarkable treatment advances beginning in the late 1970s.

Here, Dr. Tony Talebi discusses the treatment of seminoma testicular cancer with Dr. Pasquele Benedetto, professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center, including symptoms, diagnosis, staging, prognosis, surgery, radiation therapy and chemotherapy for seminoma testicular cancer.

Dr. Pasquele Benedetto credentials:

Board Certifications:

American Board of Internal Medicine
American Board of Internal Med-Hematology
American Board of Internal Med-Medical Oncology

Education:

Georgetown University
Washington, DC Undergraduate

Weill Medical College of Cornell University
New York, NY Graduate

Johns Hopkins Hospital
Baltimore, MD Residency

Memorial Sloan-Kettering Cancer Center
New York, NY Fellowship